ClinicalTrials.gg
CompletedNCT03951753Updated Mar 20, 2023Results posted

A Study of Tirzepatide in Participants With Type 2 Diabetes Mellitus (T2DM)

A Phase 1 interventional study of Tirzepatide and Semaglutide in Diabetes Mellitus, Type 2, sponsored by Eli Lilly and Company. Completed at 2 sites in Germany. Open to participants aged 20 Years to 74 Years. Per ClinicalTrials.gov, last updated 2023-03-20.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

How we know · 8 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
117
Allocation
Randomized
Ages
20 Years to 74 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 43 studies testing tirzepatide in Diabetes Mellitus, Type 2 — 7 open to participants now, 13 under way, 2 of them phase 3. Tirzepatide · Diabetes Mellitus, Type 2.

Enrollment
31st of 43
117 · median 160
Started
2019
with 7 others
Phase 1
8 of 43
none open now
Registered
9th of 43
by date
Lead sponsor
31 of 43
Eli Lilly and Company

Among the 43 studies testing tirzepatide in Diabetes Mellitus, Type 2, this one is the 31st largest by enrollment, is one of 8 that started in 2019, is one of 8 in phase 1, and was the 9th registered.

Diabetes Mellitus, Type 2

10,402 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

7 of the 43 studies testing tirzepatide in Diabetes Mellitus, Type 2 are open now, in 4 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About tirzepatide

Tirzepatide: first FDA approval 2022 (MOUNJARO), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 20 Years to 74 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies testing tirzepatide in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

This is a study for participants with type 2 diabetes mellitus. The main purpose of this study is to learn more about how tirzepatide, semaglutide and placebo affect the body's ability to respond to blood sugar levels after a meal. The study will last up to 40 weeks, including a 28-week treatment period.

03

Conditions studied

  • Diabetes Mellitus, Type 2
04

Who can participate

Ages eligible
20 Years to 74 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have T2DM for at least 6 months
  • Treated with diet and exercise and stable dose(s) of metformin, with or without 1 additional stable dose of oral antihyperglycemia medication other than metformin, 3 months prior to study entry
  • Have a (HbA1c) value at screening of ≥7% and ≤ 9.5 % if on metformin only; or ≥6.5% and ≤9.0% if on metformin in combination with oral antihyperglycemia medications other than metformin
  • Have a (BMI) between 25 and 45 kilograms per square meter (kg/m² ) inclusive, at screening; are of stable weight (±5%) >3 months prior to screening

Exclusion criteria

Exclusion Criteria:

  • Have a history of proliferative retinopathy or maculopathy as determined by the investigator based on a recent (\<1.5 years) ophthalmologic examination
  • Impaired renal estimated (eGFR) \<45 milliliters per minute per 1.73 square meters (mL/min/1.73 m²) calculated by Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI)
  • Have a history or current cardiovascular, respiratory, hepatic, renal, GI,endocrine, hematological or neurological disorders capable of significantly altering the absorption, metabolism or elimination of drugs; of constituting a risk when taking the study drug; or of interfering with the interpretation of data
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
117 participants (actual)

Study arms

  • Experimental
    Tirzepatide 15 mg

    Participants received 15 milligram (mg) tirzepatide administered subcutaneously (SC) once weekly for 28 weeks.

    Drug: Tirzepatide

  • Active comparator
    Semaglutide 1 mg

    Participants received 1 mg Semaglutide administered SC once weekly for 28 weeks.

    Drug: Semaglutide

  • Placebo comparator
    Placebo

    Participants received Placebo administered SC once weekly for 28 weeks.

    Drug: Placebo

Interventions

  • Administered SC

    Also known as: LY3298176

  • Administered SC

  • DrugPlacebo

    Administered SC

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Total Clamp Disposition Index (cDI)

    cDI is defined as the product of the M-value derived from the hyperinsulinemic euglycemic clamp over the last 30 minutes and total insulin secretion (ISR AUC0-120min) derived from the insulin secretion rate based on C-peptide using the using the deconvolution technique divided by the total glucose AUC0-120min from the hyperglycemic clamp portion of the study. Least squares (LS) mean was determined by analysis of covariance (ANCOVA) model for endpoint measures: log(Actual Measurement/Baseline) = log(Baseline) + Treatment (Type III sum of squares).

    Time frame: Baseline, Week 28

Secondary outcomes

  1. Change From Baseline in Fasting Glucose

    Fasting glucose is a test to determine sugar levels in blood sample after an overnight fast. Fasting glucose was measured prior to standardized mixed-meal tolerance tests (sMMTT). LS mean was determined by ANCOVA model for endpoint measures: Variable = Baseline + Treatment (Type III sum of squares).

    Time frame: Baseline, Week 28

  2. Change From Baseline in Postmeal Glucose

    Total AUC from time zero to 240 minutes after start of the meal \[AUC0-240min\]) during sMMTT was evaluated. LS mean was determined by ANCOVA model for endpoint measures: Variable = Baseline + Treatment (Type III sum of squares) and ANOVA model for baseline measures: Variable = Treatment (Type III sum of squares).

    Time frame: Baseline, Week 28

  3. Change From Baseline in Hemoglobin A1c (HbA1c)

    HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured primarily to identify average plasma glucose concentration over prolonged periods of time. LS mean was determined by mixed model repeated measures; (MMRM) model for post-baseline measures: Variable = Baseline + Treatment + Time + Treatment\*Time (Type III sum of squares).

    Time frame: Baseline, Week 28

  4. Change From Baseline in Total Insulin Secretion Rate During the 120-Minute Hyperglycemic Clamp (ISR0-120min)

    Total Insulin Secretion Rate During the 120-Minute Hyperglycemic Clamp (ISR0-120min) will be determined from C-peptide concentrations using the deconvolution technique. LS mean was determined by ANCOVA model for endpoint measures: log(Actual Measurement/Baseline) = log(Baseline) + Treatment (Type III sum of squares).

    Time frame: Baseline and Week 28

  5. Change From Baseline in Hyperinsulinemic Euglycemic Clamp M-value

    Hyperinsulinemic euglycemic clamp M-value is calculated from glucose infusion rate (GIR) over the last 30 minutes, corresponding to steady-state (+150 to +180 minutes), corrected for urine loss and space. LS mean was determined by ANCOVA model for endpoint measures: Variable = Baseline + Treatment (Type III sum of squares).

    Time frame: Baseline, Week 28

  6. Change From Baseline in Glucagon Concentration at Fasting

    Glucagon concentration was measured prior to sMMTT. LS mean was determined by ANCOVA model for endpoint measures: Variable = Baseline + Treatment (Type III sum of squares).

    Time frame: Baseline and Week 28

  7. Change From Baseline in Glucagon Concentration at Postmeal

    Total AUC from time zero to 240 minutes after start of the meal \[AUC0-240min\]) during sMMTT. LS mean was determined by ANCOVA model for endpoint measures: Variable = Baseline + Treatment (Type III sum of squares).

    Time frame: Baseline and Week 28

  8. Change From Baseline in Food Intake During Ad Libitum Meal

    Ad libitum meal served buffet-style. Food intake was recorded during a 45 minute period. The sum of the caloric breakdown (carbohydrates, protein, and fats) was calculated from the respective nutritional information of the food items. LS mean was determined by MMRM model for post-baseline measures: Variable = Baseline + Treatment + Time + Treatment\*Time (Type III sum of squares).

    Time frame: Baseline, Week 28

07

Results

Posted Mar 20, 2023

Participant flow

Participant flow — Overall Study
MilestoneTirzepatide 15 mgSemaglutide 1 mgPlacebo
Started454428
Completed414324
Not completed414
Withdrew: Adverse event103
Withdrew: Withdrawal by subject310
Withdrew: Lost to follow-up001

Outcome measures

PrimaryChange From Baseline in Total Clamp Disposition Index (cDI)

cDI is defined as the product of the M-value derived from the hyperinsulinemic euglycemic clamp over the last 30 minutes and total insulin secretion (ISR AUC0-120min) derived from the insulin secretion rate based on C-peptide using the using the deconvolution technique divided by the total glucose AUC0-120min from the hyperglycemic clamp portion of the study. Least squares (LS) mean was determined by analysis of covariance (ANCOVA) model for endpoint measures: log(Actual Measurement/Baseline) = log(Baseline) + Treatment (Type III sum of squares).

Time frame:
Baseline, Week 28
Reported as:
Least squares mean · pmol*m-2*L*min-2*kg-1
Change From Baseline in Total Clamp Disposition Index (cDI)
pmol*m-2*L*min-2*kg-1Tirzepatide 15 mgSemaglutide 1 mgPlacebo
Change From Baseline in Total Clamp Disposition Index (cDI)1.9 ± 0.161.1 ± 0.100.0 ± 0.03
Statistical analysis
  • Semaglutide 1 mg vs Placebo · ANCOVA · p = <0.001 · Least squares mean difference: 1.08 · 95% CI 0.87 to 1.29Data were analysed with ANCOVA in log transformed data. Results were converted back to original scale.
  • Tirzepatide 15 mg vs Placebo · ANCOVA · p = <0.001 · Least squares mean difference: 1.92 · 95% CI 1.59 to 2.24Data were analysed with ANCOVA in log transformed data. Results were converted back to original scale.
  • Tirzepatide 15 mg vs Semaglutide 1 mg · ANCOVA · p = <0.001 · Least squares mean difference: 0.84 · 95% CI 0.46 to 1.21Data were analysed with ANCOVA in log transformed data. Results were converted back to original scale.
SecondaryChange From Baseline in Fasting Glucose

Fasting glucose is a test to determine sugar levels in blood sample after an overnight fast. Fasting glucose was measured prior to standardized mixed-meal tolerance tests (sMMTT). LS mean was determined by ANCOVA model for endpoint measures: Variable = Baseline + Treatment (Type III sum of squares).

Time frame:
Baseline, Week 28
Reported as:
Least squares mean · milligrams per decilitre (mg/dL)
Change From Baseline in Fasting Glucose
milligrams per decilitre (mg/dL)Tirzepatide 15 mgSemaglutide 1 mgPlacebo
Change From Baseline in Fasting Glucose-51.4 ± 2.30-42.4 ± 2.22-4.3 ± 2.98
Statistical analysis
  • Semaglutide 1 mg vs Placebo · ANCOVA · p = <0.001 · Least squares mean difference: -38.1 · 95% CI -45.4 to -30.7
  • Tirzepatide 15 mg vs Placebo · ANCOVA · p = <0.001 · Least squares mean difference: -47.1 · 95% CI -54.6 to -39.5
  • Tirzepatide 15 mg vs Semaglutide 1 mg · ANCOVA · p = 0.006 · Least squares mean difference: -9.0 · 95% CI -15.4 to -2.6
SecondaryChange From Baseline in Postmeal Glucose

Total AUC from time zero to 240 minutes after start of the meal \[AUC0-240min\]) during sMMTT was evaluated. LS mean was determined by ANCOVA model for endpoint measures: Variable = Baseline + Treatment (Type III sum of squares) and ANOVA model for baseline measures: Variable = Treatment (Type III sum of squares).

Time frame:
Baseline, Week 28
Reported as:
Least squares mean · Milligrams per decilitre*minute
Change From Baseline in Postmeal Glucose
Milligrams per decilitre*minuteTirzepatide 15 mgSemaglutide 1 mgPlacebo
Change From Baseline in Postmeal Glucose-17414.0 ± 726.0214236.9 ± 709.53459.2 ± 947.50
Statistical analysis
  • Semaglutide 1 mg vs Placebo · ANCOVA · p = <0.001 · Least squares mean difference: -14696.1 · 95% CI -17045.0 to -12347.3
  • Tirzepatide 15 mg vs Placebo · ANCOVA · p = <0.001 · Least squares mean difference: -17873.2 · 95% CI -20239.0 to -15507.4
  • Tirzepatide 15 mg vs Semaglutide 1 mg · ANCOVA · p = 0.002 · Least squares mean difference: -3177.1 · 95% CI -5194.3 to -1159.8
SecondaryChange From Baseline in Hemoglobin A1c (HbA1c)

HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured primarily to identify average plasma glucose concentration over prolonged periods of time. LS mean was determined by mixed model repeated measures; (MMRM) model for post-baseline measures: Variable = Baseline + Treatment + Time + Treatment\*Time (Type III sum of squares).

Time frame:
Baseline, Week 28
Reported as:
Least squares mean · % of HbA1c
Change From Baseline in Hemoglobin A1c (HbA1c)
% of HbA1cTirzepatide 15 mgSemaglutide 1 mgPlacebo
Change From Baseline in Hemoglobin A1c (HbA1c)2.05 ± 0.079-1.64 ± 0.0780.29 ± 0.101
Statistical analysis
  • Semaglutide 1 mg vs Placebo · Mixed Models Analysis · p = <0.001 · Least squares mean difference: -1.93 · 95% CI -2.18 to -1.67
  • Tirzepatide 15 mg vs Placebo · Mixed Models Analysis · p = <0.001 · Least squares mean difference: -2.33 · 95% CI -2.58 to -2.08
  • Tirzepatide 15 mg vs Semaglutide 1 mg · Mixed Models Analysis · p = <0.001 · Least squares mean difference: -0.41 · 95% CI -0.63 to -0.19
SecondaryChange From Baseline in Total Insulin Secretion Rate During the 120-Minute Hyperglycemic Clamp (ISR0-120min)

Total Insulin Secretion Rate During the 120-Minute Hyperglycemic Clamp (ISR0-120min) will be determined from C-peptide concentrations using the deconvolution technique. LS mean was determined by ANCOVA model for endpoint measures: log(Actual Measurement/Baseline) = log(Baseline) + Treatment (Type III sum of squares).

Time frame:
Baseline and Week 28
Reported as:
Least squares mean · pmol/min/m^2
Change From Baseline in Total Insulin Secretion Rate During the 120-Minute Hyperglycemic Clamp (ISR0-120min)
pmol/min/m^2Tirzepatide 15 mgSemaglutide 1 mgPlacebo
Change From Baseline in Total Insulin Secretion Rate During the 120-Minute Hyperglycemic Clamp (ISR0-120min)388.6 ± 20.17286.6 ± 15.827.4 ± 7.15
Statistical analysis
  • Semaglutide 1 mg vs Placebo · ANCOVA · p = <0.001 · Least squares mean difference: 279.14 · 95% CI 245.10 to 313.18Data were analysed with ANCOVA in log transformed data. Results were converted back to original scale.
  • Tirzepatide 15 mg vs Placebo · ANCOVA · p = <0.001 · Least squares mean difference: 381.23 · 95% CI 339.29 to 423.17Data were analysed with ANCOVA in log transformed data. Results were converted back to original scale.
  • Tirzepatide 15 mg vs Semaglutide 1 mg · ANCOVA · p = <0.001 · Least squares mean difference: 102.09 · 95% CI 51.84 to 152.33Data were analysed with ANCOVA in log transformed data. Results were converted back to original scale.
SecondaryChange From Baseline in Hyperinsulinemic Euglycemic Clamp M-value

Hyperinsulinemic euglycemic clamp M-value is calculated from glucose infusion rate (GIR) over the last 30 minutes, corresponding to steady-state (+150 to +180 minutes), corrected for urine loss and space. LS mean was determined by ANCOVA model for endpoint measures: Variable = Baseline + Treatment (Type III sum of squares).

Time frame:
Baseline, Week 28
Reported as:
Least squares mean · umol/min/kg [body weight]
Change From Baseline in Hyperinsulinemic Euglycemic Clamp M-value
umol/min/kg [body weight]Tirzepatide 15 mgSemaglutide 1 mgPlacebo
Change From Baseline in Hyperinsulinemic Euglycemic Clamp M-value19.2 ± 1.9310.7 ± 1.99-0.6 ± 2.53
Statistical analysis
  • Semaglutide 1 mg vs Placebo · ANCOVA · p = <0.001 · Least squares mean difference: 11.3 · 95% CI 4.9 to 17.7
  • Tirzepatide 15 mg vs Placebo · ANCOVA · p = <0.001 · Least squares mean difference: 19.8 · 95% CI 13.4 to 26.1
  • Tirzepatide 15 mg vs Semaglutide 1 mg · ANCOVA · p = 0.003 · Least squares mean difference: 8.5 · 95% CI 3.0 to 14.0
SecondaryChange From Baseline in Glucagon Concentration at Fasting

Glucagon concentration was measured prior to sMMTT. LS mean was determined by ANCOVA model for endpoint measures: Variable = Baseline + Treatment (Type III sum of squares).

Time frame:
Baseline and Week 28
Reported as:
Least squares mean · picomoles per litre (pmol/L)
Change From Baseline in Glucagon Concentration at Fasting
picomoles per litre (pmol/L)Tirzepatide 15 mgSemaglutide 1 mgPlacebo
Change From Baseline in Glucagon Concentration at Fasting-3.6 ± 0.55-2.8 ± 0.550.8 ± 0.75
Statistical analysis
  • Semaglutide 1 mg vs Placebo · ANCOVA · p = <0.001 · Least squares mean difference: -3.6 · 95% CI -5.5 to -1.8
  • Tirzepatide 15 mg vs Placebo · ANCOVA · p = <0.001 · Least squares mean difference: -4.5 · 95% CI -6.3 to -2.6
  • Tirzepatide 15 mg vs Semaglutide 1 mg · ANCOVA · p = 0.277 · Least squares mean difference: -0.8 · 95% CI -2.4 to 0.7
SecondaryChange From Baseline in Glucagon Concentration at Postmeal

Total AUC from time zero to 240 minutes after start of the meal \[AUC0-240min\]) during sMMTT. LS mean was determined by ANCOVA model for endpoint measures: Variable = Baseline + Treatment (Type III sum of squares).

Time frame:
Baseline and Week 28
Reported as:
Least squares mean · (pmol/L)*min
Change From Baseline in Glucagon Concentration at Postmeal
(pmol/L)*minTirzepatide 15 mgSemaglutide 1 mgPlacebo
Change From Baseline in Glucagon Concentration at Postmeal-843.6 ± 86.26-502.0 ± 87.33-205.9 ± 116.31
Statistical analysis
  • Semaglutide 1 mg vs Placebo · ANCOVA · p = 0.044 · Slope: -296.1 · 95% CI -584.8 to -7.5
  • Tirzepatide 15 mg vs Placebo · ANCOVA · p = <0.001 · Least squares mean difference: -637.7 · 95% CI -925.2 to -350.2
  • Tirzepatide 15 mg vs Semaglutide 1 mg · ANCOVA · p = 0.006 · Least squares mean difference: -341.6 · 95% CI -585.2 to -97.9
SecondaryChange From Baseline in Food Intake During Ad Libitum Meal

Ad libitum meal served buffet-style. Food intake was recorded during a 45 minute period. The sum of the caloric breakdown (carbohydrates, protein, and fats) was calculated from the respective nutritional information of the food items. LS mean was determined by MMRM model for post-baseline measures: Variable = Baseline + Treatment + Time + Treatment\*Time (Type III sum of squares).

Time frame:
Baseline, Week 28
Reported as:
Least squares mean · kilocalorie (kcal)
Change From Baseline in Food Intake During Ad Libitum Meal
kilocalorie (kcal)Tirzepatide 15 mgSemaglutide 1 mgPlacebo
Change From Baseline in Food Intake During Ad Libitum Meal-348.4 ± 34.59-284.1 ± 33.94-38.6 ± 45.17
Statistical analysis
  • Semaglutide 1 mg vs Placebo · Mixed Models Analysis · p = <0.001 · Least squares mean difference: -245.5 · 95% CI -357.7 to -133.3
  • Tirzepatide 15 mg vs Placebo · Mixed Models Analysis · p = <0.001 · Least squares mean difference: -309.8 · 95% CI -423.0 to -196.6
  • Tirzepatide 15 mg vs Semaglutide 1 mg · Mixed Models Analysis · p = 0.187 · Least squares mean difference: -64.3 · 95% CI -160.3 to 31.7

Adverse events

Collected over Up to Week 32. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/28 (0%)2/28 (7.1%)18/28 (64.3%)
Semaglutide 1 mg0/44 (0%)0/44 (0%)43/44 (97.7%)
Tirzepatide 15 mg0/45 (0%)1/45 (2.2%)41/45 (91.1%)
Most frequent serious events
Most frequent serious events
EventPlaceboSemaglutide 1 mgTirzepatide 15 mg
Acute myocardial infarctionCardiac disorders1/280/440/45
Subacute pancreatitisGastrointestinal disorders1/280/440/45
UreterolithiasisRenal and urinary disorders0/280/441/45
Most frequent other events
Showing 10 of 22
Most frequent other events
EventPlaceboSemaglutide 1 mgTirzepatide 15 mg
Decreased appetiteMetabolism and nutrition disorders7/2831/4427/45
Injection site haematomaGeneral disorders12/2812/4412/45
Early satietyGeneral disorders6/2812/4416/45
DyspepsiaGastrointestinal disorders2/2814/443/45
DiarrhoeaGastrointestinal disorders6/2813/449/45
NauseaGastrointestinal disorders7/2813/4411/45
FatigueGeneral disorders2/2810/445/45
ConstipationGastrointestinal disorders0/288/446/45
EructationGastrointestinal disorders0/288/448/45
NasopharyngitisInfections and infestations3/288/447/45

Baseline characteristics

All randomized participants who received at least one dose of study drug.

Age, Categorical
Age, Categorical(Participants)Tirzepatide 15 mgSemaglutide 1 mgPlaceboTotal
<=18 years0000
Between 18 and 65 years31201869
>=65 years14241048
Age, Continuous
Age, Continuous(years)Tirzepatide 15 mgSemaglutide 1 mgPlaceboTotal
Mean61.1 ± 7.163.7 ± 5.960.4 ± 7.661.9 ± 6.9
Sex: Female, Male
Sex: Female, Male(Participants)Tirzepatide 15 mgSemaglutide 1 mgPlaceboTotal
Female1410731
Male31342186
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Tirzepatide 15 mgSemaglutide 1 mgPlaceboTotal
Hispanic or Latino0000
Not Hispanic or Latino454428117
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Tirzepatide 15 mgSemaglutide 1 mgPlaceboTotal
American Indian or Alaska Native0000
Asian0000
Native Hawaiian or Other Pacific Islander0000
Black or African American1001
White444428116
More than one race0000
Unknown or Not Reported0000
Region of Enrollment
Region of Enrollment(Participants)Tirzepatide 15 mgSemaglutide 1 mgPlaceboTotal
Germany454428117
HbA1c (%)
HbA1c (%)(percentage)Tirzepatide 15 mgSemaglutide 1 mgPlaceboTotal
Mean7.83 ± 0.727.70 ± 0.607.90 ± 0.517.80 ± 0.63
08

Study locations

2 sites
  • Profil Institut für Stoffwechselforschung
    Neuss, North Rhine-Westphalia 41460, Germany
  • Profil Mainz GmbH & Co. KG
    Mainz, Rhineland-Palatinate 55116, Germany
09

References and documents

Publications

  • Heise T, DeVries JH, Urva S, Li J, Pratt EJ, Thomas MK, Mather KJ, Karanikas CA, Dunn J, Haupt A, Milicevic Z, Coskun T. Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 Diabetes. Diabetes Care. 2023 May 1;46(5):998-1004. doi: 10.2337/dc22-1710. PubMed 36857477 ↗
  • Heise T, Mari A, DeVries JH, Urva S, Li J, Pratt EJ, Coskun T, Thomas MK, Mather KJ, Haupt A, Milicevic Z. Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial. Lancet Diabetes Endocrinol. 2022 Jun;10(6):418-429. doi: 10.1016/S2213-8587(22)00085-7. Epub 2022 Apr 22. PubMed 35468322 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2019 to primary completion in Apr 2021, 21 months.

Results were first posted in Mar 2023, 1 year 11 months after primary completion.

Of 454 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 11. This study's 21 months is above that.

Counting every sponsor, half of 516 studies reached it within 6 months; a quarter within 2 and three quarters within 14.

How these figures are worked out, and which studies are left out of them.

Registered
May 14, 2019
First posted
May 15, 2019
StartActual
Jun 28, 2019
Primary completionActual
Apr 8, 2021
CompletionActual
Apr 8, 2021
Results first posted
Mar 20, 2023
Last update
Mar 20, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 20, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03951753
Responsible party
Sponsor
First posted
May 15, 2019
Start date
Jun 28, 2019
Primary completion
Apr 8, 2021
Completion
Apr 8, 2021
Results posted
Mar 20, 2023
Last update
Mar 20, 2023

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tirzepatide

Start the discussion